er — under Bush II — was a partial PhD student of mine when he was getting his MD at Harvard and his PhD in Econ at MIT, and remains a good friend: Mark McClellen, who is interested in this stuff and remains quite influential in DC, I think). But the reason for rambling about the FDA and placebo effects is th

er — under Bush II — was a partial PhD student =f mine when he was getting his MD at Harvard and his PhD in Econ at =IT, and remains a good friend: Mark McClellen, who is interested in =his stuff and remains quite influential in DC, I think). =nbsp; But the =eason for rambling about the FDA and placebo effects

ner — under Bush II — was a pa=tial PhD student of mine when he was getting his MD at Harvard and his PhD=in Econ at MIT, and remains a good friend: Mark McClellen, who is interest=d in this stuff and remains quite influential in DC, I think). But the reason for ra=bling about the FDA and placebo effects is th

2401, under Bush II — was a partial PhD student of mine when he=was getting his MD at Harvard and his PhD in Econ at MIT, and remains a go=d friend: Mark McClellen, who is interested in this stuff and remains quit= influential in DC, I think). But the reason for rambling about the FDA and placebo eff=cts is th

Q=80Q under Bush II — was a partial PhD student of mine when he wa= getting his MD at Harvard and his PhD in Econ at MIT, and remains a good =riend: Mark McClellen, who is interested in this stuff and remains quite i=fluential in DC, I think). EFTA_R1_01919122 EFTA02667398 But the reason for rambling about

ner — under Bush II — was a pa=tial PhD student of mine when he was getting his MD at Harvard and his PhD=in Econ at MIT, and remains a good friend: Mark McClellen, who is interest=d in this stuff and remains quite influential in DC, I think). But the reas=n for rambling about the FDA and placebo effects is th